L
Linkage Biosciences
Manufacturer of genotyping kits for use in human hla and kir typing, as well as blood genotyping for rbc, rh, abo, and hpa
About Linkage Biosciences
Linkage Biosciences specializes in advanced diagnostic tests that determine donor compatibility before transplants and monitor HLA antibodies post-transplant to prevent rejection. Operating in the healthcare and biotechnology market, the company serves hospitals, transplant centers, and laboratories. Its business model revolves around the development and sale of diagnostic assays, leveraging multiplex PCR technology for simplicity and efficiency. Revenue is generated through the sale of these diagnostic kits and related services. Linkage Biosciences aims to support the transplantation community with innovative solutions and resources, particularly during challenging times like the Covid-19 pandemic.
Source: Dealroom company dataAt a glance
- Founded
- 2005
- Headquarters
- South San Francisco, United States
- Sector
- Biotechnology
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Greenhouse Capital Partners
Fisher Capital- BPBig Sky Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Linkage Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Linkage Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.